🔎 Trials Near Me

Gara Jalqabaatti › Burkitt Lymphoma › Illinois

Qorannoo klinikaalii Burkitt Lymphoma Illinois keessatti

Qorannoo 15 Burkitt Lymphoma f Illinois keessatti hirmaatuu jiru.

Magaalota Illinois keessatti

Takkalaa qorannoo (Ingiliffa)

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Lurie Children's Hospital, Chicago
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 0 hanga 18 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06173518

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • fi 4 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
366 Days – 46 Years · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • fi 7 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 39 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03150693

Blinatumomab Consolidation in Real World

  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • fi 9 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Children's Hospital-Oak Lawn, Oak Lawn
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
365 Days · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • fi 2 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 1 hanga 30 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • fi 5 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
365 Days – 25 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Chicago
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT06137118

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 7 hanga 25 · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT05082519

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Chicago
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • University of Chicago Comprehensive Cancer Center, Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 54 · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

  • University of Chicago Comprehensive Cancer Center, Chicago
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Sad-2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Chicago, Chicago
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 15 hanga 50 · Saalaa hunda · Haaromfame 09-Ful-2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Namoota walitti qabaa jira
Umuriin 18 hanga 50 · Saalaa hunda · Haaromfame 19-Wax-2025 · NCT06785324

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.